Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Francesca Palandri

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Italy

Research Interests

Explore related searches

Professors in Italy

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (18)

Andreas Reiter

Assistant Professor, MD

GERMANY

View details

Bethan Psaila

University of Oxford

UNITED KINGDOM

View details

Juan Carlos Hernandez-Boluda

Associate Professor

University of Valencia

SPAIN

View details

Novella Pugliese

Medical assistant

Università degli Studi di Napoli Federico II

ITALY

View details

Valerio De Stefano

Full Professor of Hematology

Università Cattolica del Sacro Cuore

ITALY

View details

Massimiliano BONIFACIO

University of Verona

ITALY

View details

elena rossi

Università Cattolica del Sacro Cuore

ITALY

View details

Florian Heidel

Professor, Director and Chair

Hannover Medical School

GERMANY

View details

David Ross

Flinders University School of Medicine

AUSTRALIA

View details

Jean-Jacques Kiladjian

Université Paris Cité

FRANCE

View details

Mario Tiribelli

Associate Professor in Hematology

University of Udine

ITALY

View details

Paola Guglielmelli

Associate professor

Università degli Studi di Napoli Federico II

ITALY

View details

Timothy Devos

Professor (deeltijds hoogleraar)

KU Leuven

BELGIUM

View details

Adam Mead

University of Oxford

UNITED KINGDOM

View details

haifa kathrin al-ali

University Hospital Halle (Saale)

GERMANY

View details

Tim Somervaille

Cancer Research UK Manchester Institute

UNITED KINGDOM

View details

Casey O'Connell

Associate Professor of Clinical Medicine

University of Southern California Keck School of Medicine

UNITED STATES

View details

Steffen Koschmieder

RWTH Aachen University

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Francesca Palandri

Research Interests

Explore related searches

Articles (20)

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis

Dual transfusion independence and spleen volume reduction are associated with overall survival in patients with myelofibrosis treated with momelotinib: post hoc analyses of SIMPLIFY-1 and MOMENTUM

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor–Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1

Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison

Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis

Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms

Bridging the diagnostic gap in myeloproliferative neoplasms

SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study

Association Between Transfusion Status, Hemoglobin Levels, and Patient‐Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis

Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib

Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement

Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea

Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

Real‐world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Health‐related quality of life and symptom profile of patients with BCR::ABL1‐negative myeloproliferative neoplasms: Real‐world evidence from the GIMEMA‐PROPHECY observational study

Collaborators (18)

Andreas Reiter

Bethan Psaila

Juan Carlos Hernandez-Boluda

Novella Pugliese

Valerio De Stefano

Massimiliano BONIFACIO

elena rossi

Florian Heidel

David Ross

Jean-Jacques Kiladjian

Mario Tiribelli

Paola Guglielmelli

Timothy Devos

Adam Mead

haifa kathrin al-ali

Tim Somervaille

Casey O'Connell

Steffen Koschmieder

Make your next move.